Baiyunshan announced that as of the first three quarters of 2025, its revenue increased 4.31% year on year, and net profit increased 4.78% year on year. The company focuses on the main business, promotes the development of the upper, middle and lower reaches of the industrial chain, and optimizes procurement and digital transformation. In terms of investment mergers and acquisitions, Guangzhou Pharmaceutical Phase II Fund acquired 11.04% of Nanjing Pharmaceutical's shares for 749 million yuan, and Guangzhou Pharmaceutical won 100% of Zhejiang Pharmaceutical's shares for 500 million yuan, etc. In terms of innovation, national-level platforms and the like were added in January-November, and 27 new product development projects were added. In terms of dividends, the 2024 dividend was 1,301 million yuan, accounting for 45.87%; in the first half of 2025, the dividend was 650 million yuan, accounting for 22.93%. The company is also active in information disclosure, social responsibility, and corporate governance.

Baiyunshan announced that as of the first three quarters of 2025, its revenue increased 4.31% year on year, and net profit increased 4.78% year on year. The company focuses on the main business, promotes the development of the upper, middle and lower reaches of the industrial chain, and optimizes procurement and digital transformation. In terms of investment mergers and acquisitions, Guangzhou Pharmaceutical Phase II Fund acquired 11.04% of Nanjing Pharmaceutical's shares for 749 million yuan, and Guangzhou Pharmaceutical won 100% of Zhejiang Pharmaceutical's shares for 500 million yuan, etc. In terms of innovation, national-level platforms and the like were added in January-November, and 27 new product development projects were added. In terms of dividends, the 2024 dividend was 1,301 million yuan, accounting for 45.87%; in the first half of 2025, the dividend was 650 million yuan, accounting for 22.93%. The company is also active in information disclosure, social responsibility, and corporate governance.